Navigation Links
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Date:10/12/2009

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, GI and respiratory areas. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals, and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Novartis Media Relations

    Anna Frable                         Maureen Byrne
    Novartis Pharmaceuticals            Novartis Pharmaceuticals Corporation
     Corporation
    +1 862 778 5388 (direct)            +1 862 778 1518 (direct)
    +1 732 673 5262 (mobile)            +1 201 424 2556 (mobile)
    anna.frable@novartis.com            maureen.byrne@n
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
2. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
3. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
4. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
7. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
8. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
11. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... SAN MARCOS, Texas , Nov. 21, 2014 /PRNewswire/ ... industrial hemp containing low THC, announces they are now ... is comparable to Charlotte,s Web type strains grown in ... symptoms from other neurological disorders, such as Parkinson,s, MS, ... waiting for US laws to pass, because imported CBD ...
(Date:11/21/2014)... , Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... instruments and consumables for the medical, research, and veterinary ... veterinary and research markets in the United ... stock purchase agreement to acquire 100% of QCR & ... based distribution organization. The transaction closed on November ...
(Date:11/21/2014)... MONTREAL , 21. November 2014 ... hat heute bekannt gegeben, dass ... – EMA) die Kennzeichnung als Orphan-Medizinprodukt ... Produktkandidat des Unternehmens zur Behandlung von ... eine seltene, stark beeinträchtigende genetische Krankheit, ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
... Inc. (NYSE: LDR) announced today that its Board of ... share for the second quarter of fiscal 2012. The dividend will ... on March 9, 2012. About Landauer ... services to determine occupational and environmental radiation exposure and is ...
... BRUSSELS, Feb. 28, 2012 Eli Lilly and Company (NYSE: ... global Innovation Starts Here initiative which supports Lilly,s commitment to ... the world. Two key components of this ... Innovation Fellowship Awards. Through both, Lilly scientists will collaborate with ...
Cached Medicine Technology:Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 2Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 3Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 4Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 5
(Date:11/21/2014)... CDT PLUS! 2015 represents ... includes everything needed to process dental insurance claims. ... , CDT 2015 codes are mandatory for reporting dental ... December 31, 2014. Dental professionals must use HIPAA mandated ... claims. There are significant changes in the CDT coding ...
(Date:11/21/2014)... 21, 2014 TopConsumerReviews.com recently awarded ... industry leader in the relief of depression ... feelings of sadness and depression each year and ... choices. Often, prescription drugs can produce worse side ... are expensive and require regular follow-up visits with ...
(Date:11/21/2014)... FL (PRWEB) November 21, 2014 According ... issued on June 11th, 2014, the inflating system ... rupture when the airbag inflates. The force of inflation ... shrapnel, and the metal shards may pierce the airbag’s ... vehicle’s cabin. , According to a Bloomberg Business ...
(Date:11/21/2014)... London, UK (PRWEB) November 21, 2014 ... only ISO verified healthcare professional panel, today announced two important ... appointment of Roni DasGupta as President of Market Research, Americas ... Market Research, Europe. , Ms. DasGupta joined M3 ... President and most recently Head of Sales. Roni has ...
(Date:11/21/2014)... Dennis Thompson HealthDay ... Injecting beads of gel into the wall of a still-beating ... with severe heart failure, according to a new study. ... oxygen levels and were able to walk hundreds of feet ... Douglas Mann. He is chief of the cardiovascular division at ...
Breaking Medicine News(10 mins):Health News:PMIC Announces CDT PLUS! 2015, the Ultimate Coding Reference for Dentists and Oral Surgeons 2Health News:Depression Relief Product Receives Top 5-Star Rating from TopConsumerReviews.com 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 3Health News:M3 Global Research Announces Leadership Team Promotions in US and EU 2Health News:Gel Implant Might Help Fight Heart Failure 2Health News:Gel Implant Might Help Fight Heart Failure 3
... to open blocked heart arteries a key question has ... expensive drug, abciximab, justified over use of the less-expensive ... be published in the current edition of Value in ... an e-publication, offers clinicians the first large-scale contemporary study ...
... On the Wings to Patient Safety: Innovative Solutions and Tools set ... ... Mich., Sept. 10 The Risk Management and,Patient Safety Institute (RM&PSI) ... conference. The RM&PSI, a,subsidiary of FinCor Holdings Inc. (http://www.fincorholdings.com ), ...
... accuracy and turn-around time for reimbursement, WAYNE, ... in,health information management (HIM) services and technologies, today,announced ... 2X. The key enhancement to PrecyseCode 2X is ... of the medical record,and greater efficiency and speed ...
... Wolf Haldenstein Obtain Third-Largest Settlement,in Securities Fraud Case ... Sept. 10 Judge Morris E.,Lasker of the ... has,granted final approval of a $52.5 million settlement ... Sepracor Inc., a,Massachusetts-based pharmaceutical company (Nasdaq: SEPR ...
... well known healthcare industry executive to start October ... Corporation,(NYSE: STE ) today announced that its ... 53, president and chief executive officer, effective,October 1, ... Company,s Board,effective that date. (Photo: http://www.newscom.com/cgi-bin/prnh/20070910/CLM134 ...
... Institute are the first to discover a mechanism that ... cycle and survival. Their research may result in identification ... , The results of the study appear ... PhD, assistant professor of hematology and oncology at Emory ...
Cached Medicine News:Health News:The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates 2Health News:Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals 2Health News:Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals 3Health News:$52.5 Million Settlement Against Sepracor Inc. Approved 2Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 2Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 3Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 4Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 5Health News:Emory researchers identify signaling protein for multiple myeloma 2Health News:Emory researchers identify signaling protein for multiple myeloma 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: